logo
logo

Alltrna Announces Series B Raise Of $109 Million To Advance Trna Medicines For Stop Codon Disease

Aug 09, 2023•about 2 years ago

Round Type

series b

CambridgeTherapeuticsArtificial IntelligenceBiotechnologyHealth Care

Investors

Flagship Pioneering

Description

Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA medicines to regulate the protein universe and resolve disease, today announced that it has raised $109 million in a Series B financing to advance the company's platform and first drug candidates towards the clinic for a first indication in Stop Codon Disease. The financing round included the company's founder, Flagship Pioneering, and a number of top-tier investors.

Company Information

Company

Alltrna

Location

Cambridge, Massachusetts, United States

About

Alltrna unlocks tRNA biology to treat disease. The company’s platform incorporates AI/ML tools to develop and deliver diverse programmable molecules with broad therapeutic potential. Alltrna has an unprecedented opportunity to advance a single tRNA medicine to readthrough premature stop codons and unify treatment across a wide range of diseases with the same underlying genetic mutations. Alltrna was founded in 2018 by Flagship Pioneering.

Related People

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers